ARTICLE | Clinical News

PEP005 topical ingenol mebutate gel: Phase III data

January 4, 2010 8:00 AM UTC

In the double-blind, U.S. and Australian Phase III REGION-IIb trial in about 250 patients with AK lesions on the face and scalp, 0.015% topical PEP005 applied once daily for 3 consecutive days met the...